Active Recombinant Human Chemokine (C-C Motif) Ligand 19
|Product Overview :
|Recombinant Human MIP-3b produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 77 amino acids and having a molecular mass of 8809 Dalton.
- Gene Information
- Related Products
|Cat. No. :
|This gene is one of several CC cytokine genes clustered on the p-arm of chromosome 9. Cytokines are a family of secreted proteins involved in immunoregulatory and inflammatory processes.
|Lyopohilized with no additives.
|Purity Greater than 98% as determined by: Analysis by RP-HPLC. Reducing and non-reducing SDS-PAGE.
|Macrophage inflammatory protein 3beta is fully biologically active when compared to standard. The Activity is calculated by the ability to chemoattract Human T cells using a concentration of 7-40 ng/ml.
|Physical Appearance :
|Sterile Filtered white lyophilized (freeze-dried) powder.
|Centrifuge vial before opening. When reconstituting the product, gently pipet and wash down the sides of the vial to ensure full recovery of the protein into solution. It is recommended to reconstitute the lyophilized product with sterile water at a concentration of 0.1 mg"s/ml, which can be further diluted into other aqueous solutions.
|Purity Greater than 98% as determined by :
|Analysis by RP-HPLC. Reducing and non-reducing SDS-PAGE.
|Protein Content determined by :
|UV spectroscopy at 280 nm. Analysis by RP-HPLC calibrated against a known standard. Quantitation on SDS-PAGE against a known standard.
|Endotoxin Level :
|Endotoxin level as measured by LAL is <0.01ng/ug or <0.1EU/ug.
|Amino acid sequence :
|GTNDAEDCCL SVTQKPIPGY IVRNFHYLLI KDGCRVPAVV FTTLRGRQLC APPDQPWVER IIQRLQRTSA KMKRRSS
|Lyophilized product is very stable at -20 degrees. Reconstituted material should be aliquoted and frozen at -20. It is recommended to add a carrier protein (0.1% HSA or BSA) for long term storage.
|Gene Name :
|CCL19 chemokine (C-C motif) ligand 19 [ Homo sapiens ]
|Official Symbol :
|small inducible cytokine A19; exodus-3; CK beta-11; EBI1-ligand chemokine; CC chemokine ligand 19; beta chemokine exodus-3; small inducible cytokine subfamily A (Cys-Cys), member 19; ELC; CKb11; MIP3B; MIP-3b; SCYA19; MGC34433; CCL19; Macrophage inflammatory protein 3 beta; Short name=MIP-3-beta; EBI1-ligand chemokine; Short name=ELC; Beta chemokine exodus-3; CK beta-11; C-C motif chemokine 19; ELC; MIP3B; SCYA19
|Gene ID :
|mRNA Refseq :
|Protein Refseq :
|UniProt ID :
|Chromosome Location :
|Chemokine signaling pathway; Cytokine-cytokine receptor interaction; Signaling by GPCR
|◆ Recombinant Protein
|Recombinant Human CCL19 Protein
|Recombinant Mouse Ccl19 Protein
|Recombinant Rat Ccl19 Protein, His (Fc)-Avi-tagged
|Recombinant Horse CCL19 Protein, His-tagged
|Recombinant Human CCL19 Protein, GST-Tagged
|Recombinant Human CCL19 293 Cell Lysate
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Q&As (6)Ask a question
There are still some limitations in the current research on CCL19, such as the lack of in-depth research on its specific mechanism of action and function, and the incomplete understanding of its relationship with diseases. In addition, since CCL19 is a multifunctional protein, regulating it may also have some side effects.
It has a complex relationship with other chemokines or proteins. For example, it binds to the CCR7 receptor, which directs the migration of immune cells. In addition, CCL19 interacts with other chemokines and cytokines to jointly regulate immune responses.
Therapeutic strategies for CCL19 include inhibition of its expression, modulation of its activity, or use of gene therapy. For example, some studies have shown that the use of small molecule inhibitors or antibodies against CCL19 can inhibit its activity and thus treat some CCL19-related diseases. In addition, related diseases can also be treated by regulating the expression level of CCL19.
In order to better understand the role of CCL19 in disease, further in-depth study of its specific mechanism of action and function is needed. In addition, it is also necessary to study the changes in its expression level and activity in different diseases, as well as its relationship with the occurrence and development of diseases. At the same time, it is also necessary to explore the clinical application prospects and effects of the therapeutic strategies that regulate them. This will contribute to the development of more effective treatments to improve outcomes and quality of life for patients with CCL19-related diseases.
CCL19 is mainly involved in the recruitment and activation of immune cells. It is able to exert immune defense by binding to receptors on the cell surface to direct immune cells to migrate to the site of inflammation or infection. In addition, CCL19 is also able to regulate the activation and differentiation of immune cells, affecting the type and intensity of immune responses.
Recent studies have found that CCL19 is also involved in the production and maintenance of lymphatic vessels. These processes have an important impact on the migration of immune cells and the regulation of immune responses, and also provide new ideas for the treatment of some diseases related to CCL19.
Customer Reviews (3)Write a review
The quality of the production is stable, and the batch-to-batch and intra-batch repeatability is good.
CCL19 has a complete range of specifications and is suitable for experiments of different scales.
The preparation is simple and we can do it ourselves.
Ask a Question for All CCL19 Products
Required fields are marked with *
My Review for All CCL19 Products
Required fields are marked with *